Skip to main content
  • ASM Journals
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Latest Articles
    • COVID-19 Research and News from ASM Journals
    • mSphere of Influence: Commentaries from Early Career Microbiologists
    • Archive
  • Topics
    • Applied and Environmental Science
    • Clinical Science and Epidemiology
    • Ecological and Evolutionary Science
    • Host-Microbe Biology
    • Molecular Biology and Physiology
    • Therapeutics and Prevention
  • For Authors
    • Getting Started
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About mSphere
    • Editor in Chief
    • Board of Editors
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • ASM Journals
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
mSphere
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Latest Articles
    • COVID-19 Research and News from ASM Journals
    • mSphere of Influence: Commentaries from Early Career Microbiologists
    • Archive
  • Topics
    • Applied and Environmental Science
    • Clinical Science and Epidemiology
    • Ecological and Evolutionary Science
    • Host-Microbe Biology
    • Molecular Biology and Physiology
    • Therapeutics and Prevention
  • For Authors
    • Getting Started
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About mSphere
    • Editor in Chief
    • Board of Editors
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
Commentary | Therapeutics and Prevention

mSphere of Influence: Turning to Soil for Medicines

Ching-Hsuan Lin
Ching-Hsuan Lin
aDepartment of Biochemical Science and Technology, College of Life Science, National Taiwan University, Taipei, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ching-Hsuan Lin
DOI: 10.1128/mSphere.01258-20
  • Article
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Ching-Hsuan Lin works in the field of Candida biology. In this mSphere of Influence article, he reflects on how the papers “Use of ichip for high-throughput in situ cultivation of uncultivable microbial species” by D. Nichols, N. Cahoon, E. M. Trakhtenberg, L. Pham, et al. (Appl Environ Microbiol 76:2445–2450, 2010, https://doi.org/10.1128/AEM.01754-09) and “A new antibiotic kills pathogens without detectable resistance” by L. L. Ling, T. Schneider, A. J. Peoples, A. L. Spoering, et al. (Nature 517:455–459, 2015, https://doi.org/10.1038/nature14098) made an impact on him by inspiring him to explore new bioactive antimicrobial compounds with his collaborators.

The views expressed in this article do not necessarily reflect the views of the journal or of ASM.

COMMENTARY

Although more than 5 × 1030 microorganisms have been predicted in our living place, only a few thousand can be cultivated in laboratories (1). Lewis and Epstein’s team designed a tiny diffusion chamber (Isolation Chip [iChip]) under conditions with or without specific growth factors to isolate uncultivated microorganisms (2). A new species, Eleftheria terrae, was thus successfully cultivated by using iChip. With this breakthrough, a new antibiotic compound, teixobactin, produced by E. terrae, was obtained from the extracts of 10,000 isolates, and the potential biosynthetic gene cluster of teixobactin was also identified after the genome of E. terrae was obtained (3). Lewis’s group further demonstrated in vitro and in vivo the antimicrobial mechanism of teixobactin, which involved inhibiting the synthesis of lipid II (precursor of peptidoglycan) and lipid III (precursor of teichoic acid) to effectively kill Gram-positive bacteria and their drug-resistant strains (3). Moreover, no teixobactin-resistant strain was obtained during in vitro passage, suggesting that teixobactin might reduce the likelihood that resistance will develop in the future (3). Two papers have significantly influenced my way of thinking and fueled my interest to pursue new possibilities in drug discovery.

Microbial metabolites are a rich and promising source for drug discovery. Most antibiotics we are using were discovered in 1940 to 1960, and hundreds of the most important clinical drugs are obtained from cultured microorganisms. Repeated screening for new antimicrobial drugs through the same methods and platforms within the same microorganisms resulted in catastrophic failure inevitably. Therefore, development of new techniques and platforms such as alternative culturing methods for a broader spectrum of microorganisms and the access to potential compounds via the expression of metagenomic libraries is a paramount task for the field (4). Hence, what was striking to me is that iChip is a novel, manipulatable, and effective platform for extensive isolation of uncultivable microorganisms. Indeed, the microbial growth recovery by iChip was 50 times higher than that in a standard petri dish (3). Teixobactin might not have been found without iChip. There is no doubt that together with collaborators, Lewis’s group opened a door to a new world for scientists who are enthusiastic and passionate about drug discovery.

Fungal infections have dramatically increased over the past few decades (5). Compared to the antibiotics in current use, antifungal drugs are limited, and the emergence of resistant strains is occurring worldwide. Development and discovery of novel antifungal agents are therefore an unmet need. Extracts of these bacterial isolates acquired from the iChip will be useful to discover new antifungal drugs, too. Not only that, the greatest thing is that the developed technique can be broadly applied to find new drugs for treatment of viral infections, cancers, and other diseases.

Starting a career in research as a Principal Investigator, my work was focusing on the Candida species to understand the molecular aspects and related signaling pathways in its sexual cycle and pathogenesis. The challenge I faced was that there always has been a gap between basic science (benchside) and clinical research (bedside). For example, drug development is a time-consuming, costly, and complex process. To translate fundamental scientific discoveries to clinical impacts, a multidisciplinary team is key to success. The breakthrough iChip technique certainly inspires scientists in academia like me to devote themselves to the discovery and development of new antimicrobial agents again. It certainly has impacted my career, leading me to change the research focus of my academic career. Currently, more than half of my laboratory projects are for applied science in the discovery and identification of new antifungal compounds and new therapeutic methods for the treatment of fungal infections via multidisciplinary collaboration.

  • Copyright © 2021 Lin.

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.

REFERENCES

  1. 1.↵
    1. Whitman WB,
    2. Coleman DC,
    3. Wiebe WJ
    . 1998. Prokaryotes: the unseen majority. Proc Natl Acad Sci U S A 95:6578–6583. doi:10.1073/pnas.95.12.6578.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Nichols D,
    2. Cahoon N,
    3. Trakhtenberg EM,
    4. Pham L,
    5. Mehta A,
    6. Belanger A,
    7. Kanigan T,
    8. Lewis K,
    9. Epstein SS
    . 2010. Use of ichip for high-throughput in situ cultivation of “uncultivable” microbial species. Appl Environ Microbiol 76:2445–2450. doi:10.1128/AEM.01754-09.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Ling LL,
    2. Schneider T,
    3. Peoples AJ,
    4. Spoering AL,
    5. Engels I,
    6. Conlon BP,
    7. Mueller A,
    8. Schäberle TF,
    9. Hughes DE,
    10. Epstein S,
    11. Jones M,
    12. Lazarides L,
    13. Steadman VA,
    14. Cohen DR,
    15. Felix CR,
    16. Fetterman KA,
    17. Millett WP,
    18. Nitti AG,
    19. Zullo AM,
    20. Chen C,
    21. Lewis K
    . 2015. A new antibiotic kills pathogens without detectable resistance. Nature 517:455–459. doi:10.1038/nature14098.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    1. Hover BM,
    2. Kim S-H,
    3. Katz M,
    4. Charlop-Powers Z,
    5. Owen JG,
    6. Ternei MA,
    7. Maniko J,
    8. Estrela AB,
    9. Molina H,
    10. Park S,
    11. Perlin DS,
    12. Brady SF
    . 2018. Culture-independent discovery of the malacidins as calcium-dependent antibiotics with activity against multidrug-resistant Gram-positive pathogens. Nat Microbiol 3:415–422. doi:10.1038/s41564-018-0110-1.
    OpenUrlCrossRef
  5. 5.↵
    1. Kullberg BJ,
    2. Arendrup MC
    . 2015. Invasive candidiasis. N Engl J Med 373:1445–1456. doi:10.1056/NEJMra1315399.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
Download PDF
Citation Tools
mSphere of Influence: Turning to Soil for Medicines
Ching-Hsuan Lin
mSphere Jan 2021, 6 (1) e01258-20; DOI: 10.1128/mSphere.01258-20

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print
Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this mSphere article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
mSphere of Influence: Turning to Soil for Medicines
(Your Name) has forwarded a page to you from mSphere
(Your Name) thought you would be interested in this article in mSphere.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
mSphere of Influence: Turning to Soil for Medicines
Ching-Hsuan Lin
mSphere Jan 2021, 6 (1) e01258-20; DOI: 10.1128/mSphere.01258-20
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • COMMENTARY
    • REFERENCES
  • Info & Metrics
  • PDF

KEYWORDS

uncultivable microorganisms
iChip
new antibiotic
antimicrobial compounds

Related Articles

Cited By...

About

  • About mSphere
  • Board of Editors
  • Policies
  • For Reviewers
  • For the Media
  • Embargo Policy
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Author Warranty
  • Types of Articles
  • Getting Started
  • Ethics
  • Contact Us

Follow #mSphereJ

@ASMicrobiology

       

 

Website feedback

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Online ISSN: 2379-5042